Biomarker: F093-IgE Cocoa

Overview

F093-IgE Cocoa measures immunoglobulin E (IgE) antibodies in blood that bind to cocoa allergen proteins. IgE is involved in immediate allergic reactions by activating mast cells and basophils after exposure to an allergen. A detectable or elevated result indicates sensitization to cocoa, but does not by itself confirm a clinical cocoa allergy, predict reaction severity, or establish that cocoa caused symptoms. The test is clinically useful as part of an allergy-focused evaluation when a person has a history suggestive of an immediate reaction to cocoa or chocolate; diagnosis requires correlation with clinical history and, when appropriate, a medically supervised oral food challenge.

Clinical Use Cases

Evaluating suspected IgE-mediated reactions after ingestion of cocoa or chocolate.
Supporting identification of cocoa as a possible trigger when interpreted with symptom history and other allergy testing.
Assessing sensitization in patients with suspected reactions to chocolate products, while considering exposure to milk, peanut, tree nuts, or other common ingredients and contaminants.
Supporting specialist decisions about whether further evaluation, avoidance, or a supervised oral food challenge is appropriate.
Researching the uncommon occurrence and clinical characteristics of IgE-mediated cocoa allergy.

Specimen Types

Venous blood, typically collected as serum.
Plasma may be acceptable for some validated specific-IgE platforms.

Measurement Methods

In-vitro allergen-specific IgE immunoassay using cocoa or cacao extract bound to a solid phase.
Fluorescent enzyme immunoassay.
Enzyme-linked immunosorbent assay.
Chemiluminescent immunoassay.
Immunoblot or multiplex allergen-specific IgE methods in selected clinical or research settings.
Skin-prick testing and oral food challenge are complementary clinical procedures, not measurements of F093-IgE in a blood specimen.

Test Preparation and Influencing Factors

Fasting is generally not required for an allergy blood test.
No special preparation is usually required for serum-specific IgE collection.
Antihistamines generally do not alter serum-specific IgE results, although they can affect skin-prick testing. Patients should report all medications and should not stop prescribed medicines without medical advice.
Results should be interpreted with the timing, amount, and form of cocoa exposure and the onset and nature of symptoms.
Total IgE concentration, assay platform, calibration, reporting units, and laboratory-specific decision thresholds can affect interpretation.
A positive result indicates sensitization and may occur without symptoms on exposure. A higher concentration does not reliably predict reaction severity.
Cocoa-specific IgE testing should generally be ordered when the clinical history indicates a possible IgE-mediated reaction rather than as an untargeted screening test.
Cross-contact or other chocolate ingredients, particularly milk, peanut, and tree nuts, should be considered when evaluating a reaction attributed to chocolate.